Abstract: Compositions and methods are provided for modulating the expression of the replication protein A p70 subunit and for the treatment and diagnosis of diseases associated with replication protein A p70 subunit.
Type:
Grant
Filed:
September 10, 1999
Date of Patent:
October 30, 2001
Assignees:
ISIS Pharmaceuticals, Inc., Variagenics, Inc.
Inventors:
Brett P. Monia, James P. Basilion, Vincent P. Stanton, Jr.
Abstract: Disclosed are methods for the treatment of proliferative disorders using compounds and/or environmental conditions which result in a difference in sensitivity of targeted and non-targeted cells. Certain of the methods involve the identification and use of allele-specific inhibitors of conditionally essential genes.
Type:
Grant
Filed:
March 19, 1998
Date of Patent:
March 13, 2001
Assignee:
Variagenics, Inc.
Inventors:
David E. Housman, Fred D. Ledley, Vincent P. Stanton, Jr.
Abstract: Disclosed are methods and reagents for detecting nucleotide mismatches (for example, due to sequence variances) in a nucleic acid sample involving the use of a nucleic acid probe derived from a hemizygous cell. Methods for determining the haplotype of a nucleic acid sample are also disclosed. Also disclosed are methods for producing the probe and kits containing the probe.
Abstract: Disclosed herein is a method for detecting a mismatch in a duplex nucleic acid, involving: a) contacting the duplex nucleic acid with a reactive agent under conditions which permit the agent to bind but not cleave a mismatch in said duplex nucleic acid; b) detecting binding of the agent to the duplex nucleic acid as an indication of the presence of a mismatch in the duplex nucleic acid; c) contacting the duplex nucleic acid with the reactive agent under conditions which permit the agent to cleave a mismatch in the duplex nucleic acid; and d) detecting a cleavage product as an indication of the presence of a mismatch in the duplex nucleic acid.
Type:
Grant
Filed:
February 2, 1999
Date of Patent:
August 29, 2000
Assignee:
Variagenics, Inc.
Inventors:
Borries Kemper, Karin Birkenkamp-Demtroder, Stefan Golz
Abstract: This invention is directed to a therapeutic strategy involving (1) identification of alternative alleles of genes coding for protein vital for cell viability or cell growth and the loss of one of those alleles in cancer cells due to loss of heterozygosity (LOH) and (2) the development of inhibitors with high specificity for the single remaining alternative allele of the vital gene retained by the cancer cell after LOH. The inhibitors of this invention are specific for one alternative allele of a gene that codes for a protein vital to cell viability or cell growth. The targeted gene has two alternative alleles in which the inhibitors of this invention blocks only one of the two alternative alleles, still present in the cancer cells. Exposure to the inhibitor inhibits or kills cancer cells which have undergone LOH. Protein is still capable of being expressed in the normal cells exposed to the inhibitor by the unblocked alternative allele.
Abstract: Methods are disclosed for detecting one or more mutations in an isolated test nucleic acid by forming a heteroduplex with a homologous control DNA and contacting the heteroduplex with a resolvase capable of recognizing at least one single base pair mismatch within the heteroduplex. In preferred embodiments of the invention, the resolvase is bacteriophage T4 endonuclease VII.
Type:
Grant
Filed:
September 2, 1997
Date of Patent:
September 28, 1999
Assignee:
Variagenics, Inc.
Inventors:
Richard G. H. Cotton, Rima Youil, Borries W. Kemper
Abstract: Disclosed is a method for detecting one or more mismatches between a first and a second nucleic acid, the first and second nucleic acids being capable of preferentially hybridizing.
Type:
Grant
Filed:
October 19, 1995
Date of Patent:
December 22, 1998
Assignee:
Variagenics, Inc.
Inventors:
Jeff Babon, Rima Youil, Jay Stoerker, Anne Huff, Richard G. H. Cotton